Contents
Download PDF
pdf Download XML
905 Views
356 Downloads
Share this article
Letter to the Editor | Volume 1 Issue 1 (July-Dec, 2020) | Pages 1 - 2
Consider Non-Myasthenic Neuromuscular Disorders as Major Causes of Diplopia
1
Klinik Landstrasse, Messerli Institute, Vienna, Austria
Under a Creative Commons license
Open Access
Received
July 3, 2020
Revised
Aug. 12, 2020
Accepted
Sept. 30, 2020
Published
Oct. 5, 2020
Abstract

With interest we read the review article by Margolin et al. about the causes, work-up, and treatment options of diplopia (double vision) [1]. Diplopia may be due to affection of one or both eyes. Diplopia may be permanent or transient. The author concluded that “careful history taking and basic examination skills described in the article should allow a neurologist to make an accurate diagnosis in most cases” [1]. We have the following comments and concerns.

 

The main shortcoming of the study is that a number of disorders manifesting with diplopia were not included in this review. The most prevalent among these disorders is myopathy of extra-ocular muscle. Myopathy is a major differential diagnosis of diplopia, which may or may not be associated with concomitant ptosis. Diplopia may occur in primary (genetic) and secondary (acquired) myopathies. 

 

Among the muscular dystrophies, diplopia has been particularly reported in myotonic dystrophy [2] and oculo-pharyngeal muscular dystrophy [3]. Among the congenital myopathies diplopia has been most frequently described in nemaline myopathy [4]. The most prevalent myopathic cause of diplopia is metabolic myopathy. Among the metabolic myopathies, double vision is a hallmark of mitochondrial disorders (MIDs). Diplopia occurs in syndromic and non-syndromic MIDs. Among the syndromic MIDs, diplopia occurs most frequently in patients with progressive external ophthalmoplegia (PEO), which may be due to single or multiple mtDNA deletions, mtDNA depletion, or due to point mutations in nDNA or mtDNA located genes encoding for mitochondrial proteins. Diplopia is also a frequent feature of Kearns-Sayre syndrome or Leigh syndrome. Among the hereditary transmission disorders (congenital myasthenic syndromes) diplopia has been reported in patients carrying rapsyn mutations [5]. Among the channelopathies. paramyotonia congenita may manifest with double vision.

 

Among the secondary myopathies diplopia may occur in sarcoid orbital myopathy [6]. Double vision may be a dominant manifestation of oculomotor, ocular neuromyotonia [7]. Double vision can be a manifestation of drug-induced myopathy, such as PD-1 myopathy which is due to programmed death inhibitors [8]. Other drugs causing diplopia include tremelimumab, durvalumab [9], or isotrenoin. 

 

Various subtypes of Guillain-Barre syndrome (GBS), particularly Miller- Fisher syndrome (MFS) may manifest with double vision. More rarely, acute, inflammatory, demyelinating polyneuropathy (AIDP), acute, motor, axonal neuropathy (AMAN), or Bickerstaff encephalitis may manifest   with   double   vision.   Diplopia   may   be   a   manifestation   of neuroborreliosis. Not to forget, thiamine deficiency, manifesting as Wernicke encephalopathy or beri beri, may present with double vision among other typical manifestations [10].

 

The author also did not consider double vision due to orbital compartment syndrome due to carotid cavernous fistula. Primary or secondary orbital tumours should be also considered as rare causes of diplopia. Neurologist and ophthalmologist should also consider benign or malign neoplasms of the cerebrum as causes of diplopia. Diplopia has been particularly reported in association with pituitary adenoma, but also in association with lipoma or lymphoma. 

 

Overall, work-up for diplopia should include search for primary and secondary myopathy, for immune-mediated neuropathies, for  thiamine   deficiency,  benig and malign neoplasms, traumatic brain injury, and for orbital tumours. Work-up for these neglected causes of diplopia is crucial as some of them respond favourable to treatment. Early treatment may result in a better outcome than delayed application of treatment.

Keywords
REFERENCE
  1. Margolin, E. "Approach to patient with diplopia." Journal of Neurological Sciences, vol. 417, 2020, p. 117055, doi:10.1016/j.jns.2020.117055.

  2. Thiriez, C. et al. "Ophthalmoplegia as the presenting muscle-related manifestation of myotonic dystrophy." Revue Neurologique (Paris), vol. 166, no. 5, 2010, pp. 538–541, doi:10.1016/j.neurol.2009.12.004.

  3. Goyal, N. A. et al. "Oculopharyngeal muscular dystrophy, an often misdiagnosed neuromuscular disorder: a southern California experience." Journal of Clinical Neuromuscular Diseases, vol. 21, no. 2, 2019, pp. 61–68, doi:10.1097/CND.0000000000000271.

  4. Kanatani, M. et al. "Rinsho Shinkeigaku." Clinical Neurology, vol. 60, no. 7, 2020, pp. 489–494, doi:10.5692 /clinicalneurol.60.cn-001427.

  5. Yasaki, E. et al. "Electrophysiological and morphological characterization of a case of autosomal recessive congenital myasthenic syndrome with acetylcholine receptor deficiency due to a N88K rapsyn homozygous mutation." Neuromuscular Disorders, vol. 14, no. 1, 2004, pp. 24–32, doi:10.1016/j.nmd.2003.07.002.

  6. Vahdani, K., and Rose, G. E. "Sarcoid orbital myopathy: clinical presentation and outcomes." Ophthalmic Plastic and Reconstructive Surgery, vol. 36, no. 1, 2020, pp. 61–66, doi:10.1097/IOP.0000000000001462.

  7. Padungkiatsagul, T. et al. "Bilateral oculomotor ocular neuromyotonia: a case report." BMC Neurology, vol. 18, no. 1, 2018, p. 137. Published 2018 Sep 3, doi:10.1186/s12883-018-1142-0.

  8. Liewluck, T., Kao, J. C., and Mauermann, M. L. "PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies." Journal of Immunotherapy, vol. 41, no. 4, 2018, pp. 208–211, doi:10.1097/CJI.0000 0000000001.

  9. Carrera, W. et al. "A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer." Neuro-Ophthalmology, vol. 41, no. 3, 2017, pp. 140–143. Published 2017 Mar 15, doi:10.1080/01658107. 2017.1291686.

  10. Tan, T. X. Z. et al. "Starvation-induced diplopia and weakness: a case of beriberi and Wernicke's encephalopathy." BMJ Case Reports, vol. 12, no. 1, 2019, p. e227412. Published 2019 Jan 3, doi:10.1136/bcr-2018-22741296.

Recommended Articles
Research Article
Pulmonary Function Test (PFT) and 6 Minutes’ Walk Test Findings among Interstitial Lung Diseases (ILDS) Patients in a Tertiary Care Hospital
Published: 27/11/2021
Download PDF
Research Article
Silent Threats in the Hills: Assessing Community Awareness of Hypertension and Lifestyle Risk Factors Among Adults in Shimla District
Published: 25/08/2025
Download PDF
Research Article
Screen or Suffer: Evaluating Awareness of Cervical Cancer and Pap Smear Screening Among Women in Himachal Pradesh
Published: 05/04/2025
Download PDF
Research Article
Curves of Concern: Public Awareness of Scoliosis and Its Impact on Childhood Development in Hamirpur
Published: 10/12/2024
Download PDF
Chat on WhatsApp
Flowbite Logo
Najmal Complex,
Opposite Farwaniya,
Kuwait.
Email: kuwait@iarcon.org

Editorial Office:
J.L Bhavan, Near Radison Blu Hotel,
Jalukbari, Guwahati-India
Useful Links
Order Hard Copy
Privacy policy
Terms and Conditions
Refund Policy
Others
About Us
Contact Us
Online Payments
Join as Editor
Join as Reviewer
Subscribe to our Newsletter
Follow us
MOST SEARCHED KEYWORDS
scientific journal
 | 
business journal
 | 
medical journals
 | 
Scientific Journals
 | 
Academic Publisher
 | 
Peer-reviewed Journals
 | 
Open Access Journals
 | 
Impact Factor
 | 
Indexing Services
 | 
Journal Citation Reports
 | 
Publication Process
 | 
Impact factor of journals
 | 
Finding reputable journals for publication
 | 
Submitting a manuscript for publication
 | 
Copyright and licensing of published papers
 | 
Writing an abstract for a research paper
 | 
Manuscript formatting guidelines
 | 
Promoting published research
 | 
Publication in high-impact journals
Copyright © iARCON Internaltional LLP . All Rights Reserved.